Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1276060 | 0.82 | NR1H2 (0.44) | ALDH1A1HSD11B1USP30UCHL1TSHR | |
| SCHEMBL6468249 | 0.82 | HSD11B1 (0.45) | ALDH1A1HSD11B1USP30UCHL1TSHR | |
| SCHEMBL1276058 | 0.82 | NR1H2 (0.44) | ALDH1A1HSD11B1USP30UCHL1TSHR | |
| SCHEMBL6468031 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HSD11B1USP30UCHL1TSHR | |
| SCHEMBL6466237 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HSD11B1USP30UCHL1TSHR | |
| SCHEMBL3512446 | 0.81 | RAB9A (0.43) | ALDH1A1HSD11B1USP30UCHL1TSHR | |
| SCHEMBL3512447 | 0.81 | RAB9A (0.43) | ALDH1A1HSD11B1USP30UCHL1TSHR | |
| SCHEMBL6468162 | 0.81 | ALDH1A1 (0.44) | ALDH1A1HSD11B1USP30UCHL1TSHR | |
| SCHEMBL6467149 | 0.81 | ALDH1A1 (0.44) | ALDH1A1HSD11B1USP30UCHL1TSHR | |
| SCHEMBL6466499 | 0.80 | GPR119 (0.44) | ALDH1A1HSD11B1USP30UCHL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | ALDH1A1 4160/4885HSD11B1 3266/4885USP30 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.